A prokinetic drug which lacks D2 receptor antagonistic action is which one of the following?
**Question:** A prokinetic drug which lacks D2 receptor antagonistic action is which one of the following?
A. Metoclopramide
B. Domperidone
C. Ropinirole
D. L-Dopa
**Core Concept:** Prokinetic drugs are medications that increase gastrointestinal motility, primarily targeting the stimulation of the stomach and small bowel. They are primarily used to treat conditions like gastroparesis, dyspepsia, and irritable bowel syndrome. The D2 receptor is a dopamine receptor subtype involved in gastrointestinal motility control.
**Why the Correct Answer is Right:** Domperidone is a prokinetic drug that selectively targets dopamine D2 and D3 receptors, primarily in the gastrointestinal (GI) tract, without significant D2 receptor antagonism. This selective action allows domperidone to stimulate GI motility without affecting dopamine's role in other physiological functions like cognition, mood, and motor control.
**Why Each Wrong Option is Incorrect:**
**Option A (Metoclopramide):** Metoclopramide is a prokinetic drug that exhibits D2 antagonism as well as D2 stimulation. Its combination of actions makes it a less specific prokinetic compared to domperidone.
**Option B (Ropinirole):** Ropinirole is a dopamine D2/D3 receptor agonist primarily used in the treatment of Parkinson's disease and essential tremor. It is not a prokinetic drug and lacks the properties required to be considered as an option.
**Option D (L-Dopa):** L-Dopa, an L-dihydroxyphenylalanine, is a precursor to dopamine. It is used in the treatment of Parkinson's disease and is not a prokinetic drug.
**Clinical Pearl:** This distinction between prokinetic drugs targeting dopamine receptors is crucial when choosing a medication for GI motility disorders, ensuring the drug's specific action on the gastrointestinal tract without affecting other dopaminergic functions.
**Correct Answer:** Domperidone is the correct answer as it selectively targets dopamine D2 receptors in the gastrointestinal tract without significant D2 antagonism, making it a more specific prokinetic drug compared to metoclopramide, which exhibits D2 antagonism.